Karima Chergui

Dr. Karima Chergui

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2006 in Science
Verified
Journal Article
Closed access
PDF file
PSPer Svenningsson
Per Svenningsson
KCKarima Chergui
Karima Chergui
IRIlan Rachleff
Ilan Rachleff
MFMarc Flajolet
Marc Flajolet
XZXiaoqun Zhang
Xiaoqun Zhang
PGPaul Greengard
Paul Greengard
The pathophysiology of depression remains enigmatic, although abnormalities in serotonin signaling have been implicated. We have found that the serotonin 1B receptor [5-hydroxytryptamine (5-HT 1B ) receptor] interacts with p11. p11 increases localization of 5-HT 1B receptors at the cell surface. p11 is increased in rodent brains by antidepressants or electroconvulsive therapy, but decreased in an animal model of depression and in brain tissue from depressed patients. Overexpression of p11 increases 5-HT 1B receptor function in cells and recapitulates certain behaviors seen after antidepressant treatment in mice. p11 knockout mice exhibit a depression-like phenotype and have reduced responsiveness to 5-HT 1B receptor agonists and reduced behavioral reactions to an antidepressant.

1 February 1993 in European Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
KCKarima Chergui
Karima Chergui
PCP. J. Charléty
P. J. Charléty
HAH. Akaoka
H. Akaoka
CSC. F. Saunier
C. F. Saunier
JBJ.‐L. Brunet
J.‐L. Brunet
GCG. Chouvet
G. Chouvet


1 October 1994 in Neuroscience
Verified
Journal Article
Closed access
KCKarima Chergui
Karima Chergui
MSM.F. Suaud-Chagny
M.F. Suaud-Chagny
FGF. Gonon
F. Gonon

1 April 1993 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Closed access
PDF file
LALotta Arborelius
Lotta Arborelius
KCKarima Chergui
Karima Chergui
SMSumio Murase
Sumio Murase
GNGeorge G. Nomikos
George G. Nomikos
BHBerit Backlund Höök
Berit Backlund Höök
TSTorgny H. Svensson
Torgny H. Svensson

9 February 2004 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
KCKarima Chergui
Karima Chergui
PSPer Svenningsson
Per Svenningsson
PGPaul Greengard
Paul Greengard
Dopaminergic and glutamatergic neurotransmissions in the striatum play an essential role in motor- and reward-related behaviors. Dysfunction of these neurotransmitter systems has been found in Parkinson's disease, schizophrenia, and drug addiction. Cyclin-dependent kinase 5 (CDK5) negatively regulates postsynaptic signaling of dopamine in the striatum. This kinase also reduces the behavioral effects of cocaine. Here we demonstrate that, in addition to a postsynaptic role, CDK5 negatively regulates dopamine release in the striatum. Inhibitors of CDK5 increase evoked dopamine release in a way that is additive to that of cocaine. This presynaptic action of CDK5 also regulates glutamatergic transmission. Indeed, inhibition of CDK5 increases the activity and phosphorylation of N-methyl-d-aspartate receptors, and these effects are reduced by a dopamine D1 receptor antagonist. Using mice with a point mutation of the CDK5 site of the postsynaptic protein DARPP-32 (dopamine- and cAMP-regulated phosphoprotein, molecular mass of 32 kDa), in the absence or in the presence of a dopamine D1 receptor antagonist, we provide evidence that CDK5 inhibitors potentiate dopaminergic transmission at both presynaptic and postsynaptic locations. These findings, together with the known ability of CDK5 inhibitors to prevent degeneration of dopaminergic neurons, suggest that this class of compounds could potentially be used as a novel treatment for disorders associated with dopamine deficiency, such as Parkinson's disease.